An observational study in Biliary Tract Neoplasms, sponsored by RenJi Hospital. Status unknown at 4 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-10-17.
Sponsored by RenJi Hospital · Observational
Our study aims to evaluate the role of ct-DNA and PBMC as biomarkers in the treatment of biliary tract cancer.
Biliary cancer ranked fifth in all gastrointestinal malignant cancer. Epidemiological surveys showed a significant increasing trend in recent years. How can make an early diagnosis of bile duct cancer as well as prognostic evaluation and efficacy monitoring, has become the hotspot. "liquid biopsy", which is meant to detect cancers by sequencing the DNA in a few drops of a person's blood. It may detect cancers early, even before symptoms arise, when there is just a few cells in the blood circulation.
cf-DNA in cancer patients often bears similar genetic and epigenetic features to the related tumor DNA. There is evidence that some of the cf-DNA originates from tumoral tissue. This, and the fact that cf-DNA can easily be isolated from the circulation and other body fluids of patients, makes it a promising candidate as a non-invasive biomarker of cancer. And we call the cf-DNA of tumor as ct-DNA.
Peripheral blood mononuclear cells (PBMC) is any peripheral blood cell having a round nucleus. These cells can be extracted from whole blood using ficoll, a hydrophilic polysaccharide. PBMC contains genetic material of tumor and may be applied as a biomarker.
This study aims to evaluate the role of ct-DNA and PBMC as biomarkers in the treatment of biliary tract cancer.
492 studies on the registry are indexed under Biliary Tract Neoplasms; 191 are open to participants now.
This study's planned enrollment of 30 is below the median of 160 across 68 observational studies indexed under Biliary Tract Neoplasms.
Browse Biliary Tract Neoplasms studies →RenJi Hospital is the lead sponsor of 550 studies on the registry; 248 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with suspected biliary tract cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Do radical surgery or biopsy to obtain a pathological result
Pathological diagnosis of gallbladder polyps （Cholesterol / Adenoma / Others）
Sensitivity and specificity
Time frame: intraoperative
Tumor status （worse/ maintain/ better）
the level of ct-DNA compared with the tumor burden
Time frame: 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jul 2016 (actual). Primary completion is estimated for Dec 2020, 53 months after the start.
Of 43 observational studies under Biliary Tract Neoplasms, half reached primary completion within 130 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 132. This study's planned 53 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.